| 產(chǎn)品描述： | Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K. |
| 靶點： |
IC50: 0.2 nM (Human Cathepsin K), 1 nM (Rabbit Cathepsin K);CysteineProtease |
| 體內(nèi)研究： |
Odanacatib (30 mg/kg, orally, once daily) persistently suppresses bone resorption markers and serum bone formation markers versus vehicle-treated OVX monkeys. Odanacatib displays compartment-specific effects on trabecular versus cortical bone formation, with treatment resulting in marked increases in periosteal bone formation and cortical thickness in ovariectomized monkeys whereas trabecular bone formation is reduced. The bone volume/total volume (BV/TV) and bone mineral density (BMD) of the OVX?+?ODN-h group is significantly higher than that of the OVX?+?Veh group (p?
|
| 參考文獻： |
1. Jacques Yves Gauthier, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. 2. Leung P, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011 Oct;49(4):623-635. 3. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging. 2012;7:235-47. 4. Yi C, et al. Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats. Sci Rep. 2017 Mar 17;7:44682. |
| 溶解性： |
DMSO : ≥ 25 mg/mL (47.57 mM) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.903 ml |
9.513 ml |
19.027 ml |
| 5 mM |
0.381 ml |
1.903 ml |
3.805 ml |
| 10 mM |
0.19 ml |
0.951 ml |
1.903 ml |
| 50 mM |
0.038 ml |
0.19 ml |
0.381 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京